Avantor (AVTR) Is Down 22.7% After Legal Challenges and Weak Earnings Outlook - Has Investor Confidence Shifted?

• In late October 2025, Avantor, Inc. reported a third quarter net loss of US$711.8 million and issued negative full-year revenue guidance, attributing results to competitive pressures and lost contracts, while also announcing a new US$500 million share repurchase program and introducing an advanced sterile sampling suite for bioprocess manufacturers.
• Shortly after these announcements, several law firms initiated securities class action lawsuits against Avantor, alleging misrepresentations about the company's competitive positioning and failure to disclose adverse business developments during the preceding year and a half.
• We'll examine how Avantor's recent legal challenges and weak financial updates alter the company's investment narrative and outlook.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 38 companies in the world exploring or producing it. Find the list for free.

Avantor Investment Narrative Recap

To be a shareholder in Avantor today, you would need confidence that its product innovation and cost transformation efforts can offset persistent headwinds such as margin pressures, slowing end-market demand, and competitive challenges. However, the recent string of weak earnings, lowered revenue guidance, and new class action lawsuits alleging misrepresentation around its competitive position have magnified short-term uncertainty, making the risk of prolonged profitability declines an especially material issue for the business and its outlook right now.

Among the recent announcements, Avantor’s launch of a new sterile sampling suite for bioprocess manufacturers stands out. While this product expansion highlights the company’s commitment to R&D and tailored bioproduction solutions, a key value driver in its long-term growth narrative, it arrives as ongoing legal scrutiny and lost contracts raise pressing questions about whether such innovations can effectively counteract the current competitive and margin pressures.

But despite this recent push into specialized bioprocess solutions, investors should not ignore the heightened risk arising from...

Read the full narrative on Avantor (it's free!)

Avantor's outlook forecasts $7.2 billion in revenue and $461.3 million in earnings by 2028. This projection is based on a 2.5% annual revenue growth rate and a decrease of $226.1 million in earnings from the current $687.4 million.

Uncover how Avantor's forecasts yield a $13.80 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Three private investors in the Simply Wall St Community estimate Avantor’s fair value between US$13.11 and US$46.76 per share. With margin pressures and competitive intensity now in sharper focus, you may want to see how your view compares to others before making any decisions.

Explore 3 other fair value estimates on Avantor - why the stock might be worth just $13.11!

Build Your Own Avantor Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Avantor research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Avantor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Avantor's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com